CYP17A1 and cardiovascular disorder: Administration of CYP-17 inhibitors was found to be associated with a significant increased risk of all-grade (RR=1.47; 95% CI=1.27–1.7; p < 0.00001) and grade ≥3 (RR=1.55; 95% CI=1.18–2.05; p = 0.002) cardiovascular disorders.